DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results
Media Release, July 12, 2018
BB Biotech AG reports preliminary results for 1H 2018
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2018.
Based on preliminary unaudited consolidated results, BB Biotech closed the first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the corresponding period of the previous year). As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.
BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the corresponding period.
The interim report as of June 30, 2018 will be published on July 20, 2018.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Schanz, email@example.com
Maria-Grazia Iten-Alderuccio, firstname.lastname@example.org
Claude Mikkelsen, email@example.com
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07
Tanja Chicherio, firstname.lastname@example.org
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
|Company:||BB BIOTECH AG|
|Phone:||+41 52 624 08 45|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX|
|End of Announcement||DGAP News Service|
703867 12-Jul-2018 CET/CEST